ScholarMate
English简体中文繁體中文
客服熱線:400-1616-289
登入註冊
期刊論文

The Effect of Aspirin on the Primary Prevention of Major Adverse Cardiac and Cerebrovascular Events in Chinese Older Adults: A Registration Study

Sun, Xiaojia*; Sun, Ruihong; Zhang, Liming哈尔滨医科大学; 1
Drugs and Aging2022-1DOI: 10.1007/s40266-021-00906-x
8閱讀
引用收藏
分享

摘要

Background Low-dose acetylsalicylic acid (aspirin) prevents stroke and myocardial infarction in patients with cardiovascular disease (CVD), but whether it should be used for primary CVD prevention in older Chinese adults remains unclear. Methods This prospective study investigated Chinese people aged > 70 years participating in the Kadoorie Study of Chronic Disease. The subjects were grouped as aspirin users and nonusers. Propensity score matching (PSM) was used to achieve balanced baseline characteristics. The primary outcome was major adverse cardiac and cerebrovascular events (MACCE). The secondary outcomes were all-cause mortality, cardiovascular and/or cerebrovascular disease (CCVD) mortality, and bleeding events. Survival curves were used to compare the outcomes between groups. Cox regression was used to identify the risk factors for the outcomes. Results In total, 4791 participants were categorized as aspirin users (n = 257) or nonusers (n = 4534). PSM resulted in 252 and 951 participants in the aspirin user and nonuser groups, respectively. Median follow-up was 8.6 years. Aspirin did not influence MACCE, all-cause mortality, or bleeding events, but it did influence CCVD deaths (p = 0.019). Male sex (hazard ratio [HR] 1.652; 95% confidence interval [CI] 1.217-2.243; p = 0.001), body mass index (BMI) (HR 1.053; 95% CI 1.008-1.100; p = 0.021), and systolic blood pressure (HR 1.009; 95% CI 1.003-1.016; p = 0.004) were independent risk factors for MACCE. Survival analysis showed higher rates of CCVD mortality among aspirin users (HR 1.363; 95% CI 1.040-1.786; p = 0.025), but this was not significant in the regression analysis. Conclusions There were no significant benefits from using aspirin as primary prevention for MACCE in older Chinese adults.

學科與關鍵詞

關鍵詞
CARDIOVASCULAR-DISEASECOLLABORATIVE METAANALYSISHEART-DISEASEASSOCIATIONMORTALITYKADOORIESTROKE
相關
載入中…
  • Efficacy and safety of clopidogrel versus aspirin monotherapy for secondary prevention in patients with coronary artery disease: a meta-analysis
    Liu, Di; Xu, Wei Pan; Xu, Hang; Zhao, Lin*; Jin, Dao Qun*Frontiers in Cardiovascular Medicine, 2023, 10: 1265983.
  • Patient Preferences of Low-Dose Aspirin for Cardiovascular Disease and Colorectal Cancer Prevention in Italy: A Latent Class Analysis
    Tervonen, Tommi*; Vora, Pareen; Seo, Jaein; Krucien, Nicolas; Marsh, Kevin; De Caterina, Raffaele; Wissinger, Ulrike; Soriano Gabarro, MontsePatient-Patient Centered Outcomes Research, 2021, 14(5): 661-672.被引 2
  • Incremental Benefit of Lipid Lowering in a Large Chinese Population Aged 75 Years and Older With Established Atherosclerotic Cardiovascular Disease
    Lin, Zhongqiu; Chen, Yanmei; Xiao, Zhiwen; Xu, Wenlong; Chen, Guojun; Huang, Chixiong; Feng, Weijing; Xie, Zhiquan; Liao, Wangjun; Liao, Yulin; Bin, Jianping*; Feng, Li*; Wang, Shifei*Mayo Clinic Proceedings, 2023, 98(9): 1280-1296.被引 1
查看全部 →

發表資訊

論文狀態
公開發表
期刊
Drugs and Aging
發表日期
2022-01
卷期
第 39 卷, 第 1 期
頁碼
97-106
DOI
10.1007/s40266-021-00906-x
語言
ENGLISH
成果收錄
SCIE
資助標註
National Key Research and Development Program of China [2016YFC0900500, 2016YFC0900501, 2016YFC0900504]; Kadoorie Charitable Foundation in Hong Kong; Wellcome Trust in the UK [202922/Z/16/Z, 088158/Z/09/Z, 104085/Z/14/Z]

作者

  • S

    Sun, Xiaojia (通訊) (第一作者)

    1 · harbin med univ

  • S

    Sun, Ruihong

    1 · harbin med univ

查看全部 3 位作者收起作者
  • Z

    Zhang, Liming

    1 · harbin med univ

登入解鎖更多功能

  • 收藏這篇,隨時在「我的 · 收藏」找回
  • 認領你的成果,生成推廣素材
  • 關注作者獲取最新成果
  • 加入項目組、協同寫作
註冊 / 登入

產品服務

  • 科研之友
  • 創新城
  • 科創雲

服務支援

  • 幫助中心
  • 隱私政策
  • 服務條款

聯絡方式

線上客服:【】
客服熱線:400-1616-289
電子郵件:support@scholarmate.com

關注或下載科研之友

微信 QR Code
微信公眾號
客戶端下載 QR Code
下載客戶端
科研成果科研人員科研機構科研動態愛瑞思軟件

©2026 深圳市科研之友网络服务有限公司

公安備案圖示粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417